Abstract
The HERACLES-A trial demonstrated trastuzumab and lapatinib (T+L) activity in HER2-amplified (HER2+) KRAS exon 2 wild-type metastatic colorectal cancer (mCRC). We conducted the HERACLES RESCUE trial to test whether therapeutic sequencing with another anti-HER2 regimen at progression to T+L is active in these patients.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
